Articles

April 22, 2020: Wholesale Supply Channels: COVID-19 Impact on Cancer Care and Road to Recovery

How does COVID-19 affect the distribution channels that deliver crucial medicine and other supplies for patients with cancer? In ths discussion, thought leaders in the wholesale drug distribution segment focused on the disruption and interventions brought about by the COVID-19 pandemic.

April 17, 2020: Revenue Cycle Management: COVID-19 Impact on Cancer Care and Road to Recovery

By Brian Gockerman, MBA; Parag Shah; Burt Zweigenhaft, PhD, D.Litt

COVID-19

In this webcast, Brian Gockerman, Managing Director at Unlimited Systems, begins by discussing the stabilization of cancer care programs, the potential implications of telehealth, the decline of newly referred patients, and what to prepare for in the future. Parag Shah, President, Practice Solutions at Integra Connect, continues the conversation by discussing how to keep your team engaged when working remotely, the shift of solution providers and telehealth, payer challenges, and solutions to some of these issues.

The Association for Value-Based Cancer Care Launches Webinar Series: COVID-19 Impact on the Cancer Care Delivery Ecosystem

COVID-19

Cranbury, NJ – Fueled by the success of its live webcast earlier this month, the Association for Value-Based Cancer Care (AVBCC) is launching a free webinar series titled COVID-19 Impact on the Cancer Care Delivery Ecosystem.

Welcoming Opening Remarks

By Clifford Hudis, MD, FACP, FASCO; Burt Zweigenhaft, PhD, D.Litt

COVID-19

The Association for Value-Based Cancer Care (AVBCC) webcast was introduced by Dr Zweigenhaft, Founder of AVBCC, who assembled an exceptional group of experts from across the country to discuss the COVID-19 outbreak and its impact on the healthcare industry. After a few quick welcoming remarks to allow more time for the fast-moving presentations, Dr Zweigenhaft introduced Dr Hudis, who briefly presented ASCO’s outlook on the crisis.

Washington and Public Policy: The COVID-19 Pandemic

By Scott Gottlieb, MD; Jayson Slotnik, JD, MPH

COVID-19

Mr Slotnik opened the session with an inside look at Washington, addressing some of the changes to oncology care policies and operations from the COVID-19 pandemic. He outlined a quick overview of the initiatives from the Centers for Medicare & Medicaid Services (CMS), including new guidelines and the easing of some restrictions on physicians’ options for telemedicine.

Community Care Providers and COVID-19

By Lucio Gordan, MD; Ted Okon, MBA; Jeff Patton, MD

COVID-19

Up to 65% of cancer care is delivered via community cancer centers that are not part of a hospital or academic center. These centers are feeling the impact of COVID-19 as the pandemic reshapes the way these facilities provide care to patients.

Comprehensive Cancer Care Systems

By Pat Basu, MD, MBA; Robert W. Carlson, MD; Christian Downs, MHA, JD

COVID-19

According to the NCCN, an alliance of 30 leading academic cancer centers in the United States, the data suggest that although patients with cancer are not more susceptible to infection from the new coronavirus than other people, they do have much worse outcomes. “Prevention is thus the key for oncology patients,” Dr Carlson said.

Wholesale Supply Channels Addressing the Pandemic

By Barry Fortner, PhD; Tommy Pourmahram

COVID-19

Turning from the provision of care to the provision of therapies and essential personal protective equipment (PPE), Mr Pourmahram and Dr Fortner focused on the wholesale supply chain and the challenges of ensuring an uninterrupted flow of crucial materials to areas with the greatest demand.

Managed Care Payers During the Pandemic

By Scott Breidbart, MD, MBA; Matthew Eyles; Steven Peskin, MD, MBA, FACP

COVID-19

Dr Peskin, Dr Breidbart, and Mr Eyles gave an overview of the changes the novel coronavirus has prompted for managed care payers. They agreed that the unprecedented set of circumstances surrounding the pandemic has led to an opening of the floodgates to questions without immediate answers, leaving providers and payers in unfamiliar territory in a rapidly changing environment with few guideposts.

Pharmaceutical Manufacturers’ Response to COVID-19

By Eric Dozier; Julie Gerberding, MD; Brian Morrissey

COVID-19

The healthcare supply channel is dependent on drug manufacturers and their innovation and production. Representing 3 of the major biopharmaceutical companies, Dr Gerberding, Mr Morrissey, and Mr Dozier discussed the drug manufacturers’ response to the COVID-19 pandemic, announcing a recent collaboration in the fight against the novel coronavirus.

Articles

Top Trending Articles

Stay In The Know

Articles

Page 77 of 329

Top Trending Articles

Stay In The Know